HRP20191029T1 - Derivati morfinana radi liječenja predoziranja lijekom - Google Patents
Derivati morfinana radi liječenja predoziranja lijekom Download PDFInfo
- Publication number
- HRP20191029T1 HRP20191029T1 HRP20191029TT HRP20191029T HRP20191029T1 HR P20191029 T1 HRP20191029 T1 HR P20191029T1 HR P20191029T T HRP20191029T T HR P20191029TT HR P20191029 T HRP20191029 T HR P20191029T HR P20191029 T1 HRP20191029 T1 HR P20191029T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- use according
- period
- overdose
- opioid
- Prior art date
Links
- 208000003870 Drug Overdose Diseases 0.000 title claims 5
- 206010033296 Overdoses Diseases 0.000 title claims 5
- 231100000725 drug overdose Toxicity 0.000 title claims 4
- INAXVFBXDYWQFN-XHSDSOJGSA-N morphinan Chemical class C1C2=CC=CC=C2[C@]23CCCC[C@H]3[C@@H]1NCC2 INAXVFBXDYWQFN-XHSDSOJGSA-N 0.000 title 1
- 229940051807 opiod analgesics morphinan derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 27
- 206010070863 Toxicity to various agents Diseases 0.000 claims 6
- 208000024891 symptom Diseases 0.000 claims 5
- 208000012488 Opiate Overdose Diseases 0.000 claims 4
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical group O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims 4
- 229960004127 naloxone Drugs 0.000 claims 4
- 230000003247 decreasing effect Effects 0.000 claims 3
- 229940005483 opioid analgesics Drugs 0.000 claims 3
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 claims 2
- 229940123257 Opioid receptor antagonist Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000003401 opiate antagonist Substances 0.000 claims 2
- 230000001988 toxicity Effects 0.000 claims 2
- 231100000419 toxicity Toxicity 0.000 claims 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical class OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 1
- 206010010071 Coma Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 206010046555 Urinary retention Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000008784 apnea Diseases 0.000 claims 1
- 230000036760 body temperature Effects 0.000 claims 1
- 230000036471 bradycardia Effects 0.000 claims 1
- 208000006218 bradycardia Diseases 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000004478 pupil constriction Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 230000036387 respiratory rate Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Claims (21)
1. Spoj koji sadrži formulu:
za uporabu u postupku liječenja toksičnosti lijeka ili predoziranja lijekom kod subjekta kojem je nužno.
2. Spoj za uporabu sukladno patentnom zahtjevu 1, pri čemu navedena toksičnost ili predoziranje lijekom nastaje kao rezultat primjene opioida pacijentu koji nije ovisnik.
3. Spoj za uporabu sukladno patentnom zahtjevu 1 ili patentnom zahtjevu 2, pri čemu navedeni subjekt ima iskustvo s opioidom, a nije ovisnik o opoidima.
4. Spoj za uporabu sukladno patentnom zahtjevu 1, pri čemu se navedeni spoj primjenjuje u dnevnoj dozi od oko 3 do oko 20 mg/dnevno.
5. Spoj za uporabu sukladno patentnom zahtjevu 4, pri čemu je navedena dnevna doza oko 10 mg/dan.
6. Spoj za uporabu sukladno patentnom zahtjevu 1, pri čemu primjena spoja smanjuje simptome toksičnosti ili predoziranja lijekom tijekom perioda od najmanje 15 do oko 30 minuta.
7. Spoj za uporabu sukladno patentnom 6, pri čemu su simptomi predoziranja lijekom smanjeni za period od najmanje jednog sata, period od najmanje dva sata, period od najmanje tri sata, period od najmanje četiri sata ili period od najmanje osam sati.
8. Spoj za uporabu sukladno patentnom zahtjevu 6 ili patentnom zahtjevu 7, pri čemu navedena primjena sadrži oko 3 mg do oko 20 mg spoja.
9. Spoj za uporabu sukladno patentnom zahtjevu 6 ili patentnom zahtjevu 7, pri čemu su navedeni simptomi predoziranja odabrani iz smanjene brzine disanja, smanjene dubine disanja, apnee, komatoze, hipoksije, delirijske hipotenzije, bradikardije, smanjene temperature tijela, zadržavanja urina i suženja zjenica.
10. Spoj koji sadrži formulu:
za uporabu u postupku liječenja opioidne toksičnosti ili predoziranja kod subjekta kojem je potrebno sadrži isporuku prvog antagonista receptora opioida nakon čega slijedi taj spoj.
11. Spoj za uporabu sukladno patentnom zahtjevu 10, pri čemu je prvi antagonist receptora opioida nalokson.
12. Spoj za uporabu sukladno patentnom zahtjevu 10 ili patentnom zahtjevu 11, pri čemu je navedeni subjekt korisnik opoida koji ima iskustvo s opioidom ali nije ovisnik.
13. Spoj za uporabu sukladno patentnom zahtjevu 11, pri čemu nabedenoj primjeni prethodi navedena primjena naloksona.
14. Spoj za uporabu sukladno patentnom zahtjevu 13, pri čemu navedena primjena naloksona smanjuje simptome predoziranja ili toksičnosti prije primjene spoja.
15. Spoj za uporabu sukladno patentnom zahtjevu 11, pri čemu se nalokson primjenjuje istodobno s tim spojem.
16. Spoj od formule:
za uporabu u postupku liječenja akutne opioidne toksičnosti ili predoziranja tijemom razdoblja od preko jednog sata sadrži jednokratnu primjenu navedenog spoja subjektu kojem je nužno.
17. Spoj za uporabu sukladno patentnom zahtjevu 16, pri čemu je navedeni subjekt opioidno iskusan pacijent koji nije ovisnik.
18. Spoj za uporabu sukladno patentnom zahtjevu 16, pri čemu su simptomi opioidne toksičnosti ili predoziranja smanjeni tijekom razdoblja od više od jednog sata, tijekom razdoblja od više od četiri sata, tijekom razdoblja od više od osam sati ili tijekom razdoblja od više od dvadeset četiri sata.
19. Spoj od formule:
radi uporabe u postupku za nekontrolirano liječenje opioidne toksičnosti ili predoziranja opioidom kod pacijenta kojem je nužno.
20. Spoj za uporabu sukladno patentnom zahtjevu 19, pri čemu je navedeno nekontrolirano liječenje djelotvorno tijekom razdoblja od preko jedog sata..
21. Sol L-malata koja sadrži formulu:
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26688109P | 2009-12-04 | 2009-12-04 | |
| PCT/US2010/052437 WO2011068594A1 (en) | 2009-12-04 | 2010-10-13 | Morphinan derivatives for the treatment of drug overdose |
| EP10834900.2A EP2506712B8 (en) | 2009-12-04 | 2010-10-13 | Morphinan derivatives for the treatment of drug overdose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191029T1 true HRP20191029T1 (hr) | 2019-09-20 |
Family
ID=44082631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191029TT HRP20191029T1 (hr) | 2009-12-04 | 2019-06-07 | Derivati morfinana radi liječenja predoziranja lijekom |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US9119848B2 (hr) |
| EP (2) | EP2506712B8 (hr) |
| JP (2) | JP5691042B2 (hr) |
| AU (1) | AU2010326676B2 (hr) |
| CA (1) | CA2782529C (hr) |
| CY (1) | CY1121646T1 (hr) |
| DK (1) | DK2506712T3 (hr) |
| ES (1) | ES2729679T3 (hr) |
| HR (1) | HRP20191029T1 (hr) |
| HU (1) | HUE043963T2 (hr) |
| LT (1) | LT2506712T (hr) |
| ME (1) | ME03468B (hr) |
| NZ (1) | NZ600379A (hr) |
| PL (1) | PL2506712T3 (hr) |
| PT (1) | PT2506712T (hr) |
| RS (1) | RS58894B1 (hr) |
| SI (1) | SI2506712T1 (hr) |
| SM (1) | SMT201900357T1 (hr) |
| TR (1) | TR201908514T4 (hr) |
| WO (1) | WO2011068594A1 (hr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104958298A (zh) * | 2009-09-18 | 2015-10-07 | 阿得罗公司 | 阿片样受体拮抗剂用于胃肠道疾病的用途 |
| TR201908514T4 (tr) * | 2009-12-04 | 2019-07-22 | Alkermes Pharma Ireland Ltd | İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇ |
| HRP20240109T1 (hr) | 2010-08-23 | 2024-03-29 | Alkermes Pharma Ireland Limited | Postupci za liječenje povećanja tjelesne težine induciranog antipsihoticima |
| US8627816B2 (en) * | 2011-02-28 | 2014-01-14 | Intelliject, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
| US8939943B2 (en) | 2011-01-26 | 2015-01-27 | Kaleo, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
| HUE041883T2 (hu) * | 2011-12-15 | 2019-06-28 | Alkermes Pharma Ireland Ltd | Samidorphan (ALKS 33) és buprenorfin kombináció, depressziós zavarok kezelésére |
| HUE044957T2 (hu) * | 2011-12-15 | 2019-11-28 | Alkermes Pharma Ireland Ltd | Samidorphan (ALKS 33) opioid agonistákkal alkotott kombinációja |
| US10195191B2 (en) | 2011-12-15 | 2019-02-05 | Alkermes Pharma Ireland Limited | Opioid agonist antagonist combinations |
| US9211293B2 (en) | 2011-12-15 | 2015-12-15 | Alkermes Pharma Ireland Limited | Opioid agonist antagonist combinations |
| WO2014190271A2 (en) | 2013-05-24 | 2014-11-27 | Alkermes Pharma Ireland Limted | Methods for treating depressive symptoms |
| JP2016519161A (ja) | 2013-05-24 | 2016-06-30 | アルカームス ファーマ アイルランド リミテッド | モルファン及びモルフィナン類似物及び使用の方法 |
| WO2015099863A1 (en) | 2013-12-27 | 2015-07-02 | Purdue Pharma L.P. | 6-substituted and 7-substituted morphinan analogs and the use thereof |
| JP6360915B2 (ja) * | 2014-06-13 | 2018-07-18 | パーデュー、ファーマ、リミテッド、パートナーシップ | アザモルフィナン誘導体及びその使用 |
| US9517307B2 (en) | 2014-07-18 | 2016-12-13 | Kaleo, Inc. | Devices and methods for delivering opioid antagonists including formulations for naloxone |
| US9763572B2 (en) * | 2015-02-17 | 2017-09-19 | Children's Hospital Medical Center | Quantitative pupillometry as a bedside predictor of postoperative respiratory depression |
| EP4243768A1 (en) | 2020-11-12 | 2023-09-20 | Alkermes Pharma Ireland Limited | Immediate release multilayer tablet |
| CN118598813B (zh) * | 2024-08-08 | 2024-10-29 | 山东齐都药业有限公司 | L-苹果酸萨米多芬及其制备方法 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB874217A (en) | 1958-10-30 | 1961-08-02 | Albert Boehringer | Normorphine derivatives |
| US3332950A (en) | 1963-03-23 | 1967-07-25 | Endo Lab | 14-hydroxydihydronormorphinone derivatives |
| CH581624A5 (hr) | 1970-08-14 | 1976-11-15 | Sumitomo Chemical Co | |
| US3856795A (en) * | 1972-04-25 | 1974-12-24 | American Home Prod | Process for preparation of secondary amines from tertiary amines |
| DE2254298A1 (de) | 1972-11-06 | 1974-05-16 | Boehringer Sohn Ingelheim | Neue (heteroarylmethyl)-normorphine, deren saeureadditionssalze, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
| US4032529A (en) * | 1974-09-20 | 1977-06-28 | Sterling Drug Inc. | Aminomethanobenzazocine intermediates |
| US3957793A (en) * | 1974-09-20 | 1976-05-18 | Sterling Drug Inc. | Hydroxyiminobenzazocines |
| US4127577A (en) * | 1975-11-24 | 1978-11-28 | Sterling Drug Inc. | Aminomethanobenzazocine process |
| US4205171A (en) * | 1976-01-12 | 1980-05-27 | Sterling Drug Inc. | Aminomethanobenzazocines and nitromethanobenzazocines |
| US4161597A (en) | 1976-12-20 | 1979-07-17 | Research Corporation | N-alkyl-14-hydroxymorphinans and derivatives |
| US4100228A (en) | 1977-04-04 | 1978-07-11 | The Dow Chemical Company | Transparent impact styrene polymer structure |
| US4176186A (en) | 1978-07-28 | 1979-11-27 | Boehringer Ingelheim Gmbh | Quaternary derivatives of noroxymorphone which relieve intestinal immobility |
| US4373139A (en) | 1979-04-30 | 1983-02-08 | Motorola, Inc. | Detectors |
| US4464378A (en) * | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
| FR2514644A1 (fr) | 1981-10-19 | 1983-04-22 | Sanofi Sa | Composition pharmaceutique a action antagoniste peripherique des opiaces |
| US4374139A (en) | 1981-11-09 | 1983-02-15 | Hoffmann-La Roche Inc. | Levorotatory N-substituted acylmorphinans useful as analgesic agents |
| DE3220831A1 (de) | 1982-06-03 | 1983-12-08 | Boehringer Ingelheim KG, 6507 Ingelheim | N-(2-methoxyethyl)-noroxymorphon, dessen saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu deren herstellung |
| US4451470A (en) | 1982-07-06 | 1984-05-29 | E. I. Du Pont De Nemours And Company | Analgesic, antagonist, and/or anorectic 14-fluoromorphinans |
| US4649200A (en) * | 1986-05-08 | 1987-03-10 | Regents Of The University Of Minnesota | Substituted pyrroles with opioid receptor activity |
| US4939264A (en) | 1986-07-14 | 1990-07-03 | Abbott Laboratories | Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies |
| US4929622A (en) | 1987-09-24 | 1990-05-29 | Hoechst-Roussel Pharmaceuticals, Inc. | 2,6-Methanopyrrolo-3-benzazocines |
| US5250542A (en) | 1991-03-29 | 1993-10-05 | Eli Lilly And Company | Peripherally selective piperidine carboxylate opioid antagonists |
| US5270328A (en) | 1991-03-29 | 1993-12-14 | Eli Lilly And Company | Peripherally selective piperidine opioid antagonists |
| US5159081A (en) | 1991-03-29 | 1992-10-27 | Eli Lilly And Company | Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists |
| US5258386A (en) * | 1991-06-05 | 1993-11-02 | The United States Of America As Represented By The Secretary Of The Army | (+)-3-substituted-N alkylmorphinans, synthesis and use as anticonvulsant and neuroprotective agents |
| US5607941A (en) * | 1992-06-26 | 1997-03-04 | Boehringer Ingelheim Kg | Useful for treating neurodegenerative diseases |
| SE9103745D0 (sv) | 1991-12-18 | 1991-12-18 | Wikstroem Haakan | Aryl-triflates and related compounds |
| EP0632041A1 (en) | 1993-07-01 | 1995-01-04 | Katholieke Universiteit Nijmegen | New morphine derivatives having improved analgesic and narcotic properties |
| US5434171A (en) | 1993-12-08 | 1995-07-18 | Eli Lilly And Company | Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates |
| AU706370B2 (en) * | 1996-01-10 | 1999-06-17 | Smithkline Beecham Spa | Heterocycle-condensed morphinoid derivatives (II) |
| GB9616253D0 (en) | 1996-08-01 | 1996-09-11 | Johnson Matthey Plc | Preparation of narcotic analgesics |
| ES2121553B1 (es) | 1996-12-23 | 1999-06-16 | Univ Santiago Compostela | Nuevos endoperoxidos morfinicos funcionalizados en posiciones c-6 y c-14 del anillo c y procedimiento para su obtencion. |
| GB9709972D0 (en) | 1997-05-19 | 1997-07-09 | Pfizer Ltd | Tetrazoles |
| GB9912411D0 (en) * | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
| JP4890710B2 (ja) | 1999-08-13 | 2012-03-07 | サザン・リサーチ・インスティテュート | ピリドモルフィナン類、チエノモルフィナン類及びそれらの使用 |
| MXPA02005335A (es) | 1999-11-29 | 2003-01-28 | Adolor Corp | Metodos y composiciones novedosos que incluyen opioides y antagonistas de los mismos. |
| ES2239170T3 (es) | 2000-10-31 | 2005-09-16 | Rensselaer Polytechnic Institute | 2,6-metano-3-benzazocinas sustituidas en posicion 8 y morfinanos sustituidos en posicion 3 como agentes ligantes a receptores opioides. |
| US7375082B2 (en) | 2002-02-22 | 2008-05-20 | Shire Llc | Abuse-resistant hydrocodone compounds |
| JP2005528359A (ja) | 2002-03-20 | 2005-09-22 | ユーロ−セルティーク エス．エイ． | うつ病の治療のためのブプレノルフィンの投与方法 |
| ES2249722T3 (es) | 2002-05-30 | 2006-04-01 | Eli Lilly And Company | Antagonistas de receptor de opioides. |
| EP1530723A1 (en) | 2002-07-03 | 2005-05-18 | Spinelix | 3d microarray |
| DE10229842A1 (de) | 2002-07-03 | 2004-02-05 | Helmut Prof. Dr. Schmidhammer | Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung |
| WO2004007449A1 (en) | 2002-07-16 | 2004-01-22 | Rensselaer Polytechnic Institute | Process for conversion of phenols to carboxamides via the succinimide esters |
| AU2003298691A1 (en) | 2002-11-18 | 2004-06-15 | The Mclean Hospital Corporation | Mixed kappa/mu opioids and uses thereof |
| US20040192715A1 (en) * | 2003-02-05 | 2004-09-30 | Mark Chasin | Methods of administering opioid antagonists and compositions thereof |
| EP2316456B1 (en) | 2003-04-29 | 2017-06-14 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss comprising an opioid antagonist and bupropion |
| JP2007533733A (ja) | 2004-04-22 | 2007-11-22 | モル リサーチ アプリケーションズ リミテッド | 食物摂取管理の方法 |
| CN1984879B (zh) * | 2004-05-14 | 2011-07-27 | 詹森药业有限公司 | 甲酰胺基阿片样化合物 |
| US20060063792A1 (en) | 2004-09-17 | 2006-03-23 | Adolor Corporation | Substituted morphinans and methods of their use |
| SI2251330T1 (sl) * | 2004-11-05 | 2012-09-28 | Rensselaer Polytech Inst | 4-hidroksibenzomorfani |
| AU2006220682B2 (en) | 2005-03-07 | 2012-05-31 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| EP1924559B1 (en) | 2005-07-21 | 2014-04-16 | Rensselaer Polytechnic Institute | 8-carboxamido-substituted-2 , 6-methano-3-benzazocines and 3 - carboxamido- substituted morphanes as opioid receptor binding agents |
| US20070099947A1 (en) * | 2005-11-03 | 2007-05-03 | Alkermes, Inc. | Methods and compositions for the treatment of brain reward system disorders by combination therapy |
| WO2007067714A2 (en) | 2005-12-08 | 2007-06-14 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
| US20090214650A1 (en) * | 2006-02-01 | 2009-08-27 | Alkermes, Inc. | Methods of Treating alcoholism and alcohol related disorders using combination drug therapy and swellable polymers |
| NZ575620A (en) | 2006-09-20 | 2010-11-26 | Mallinckrodt Inc | Preparation of substituted morphinan-6-ones and salts and intermediates thereof |
| US20080234306A1 (en) | 2006-11-22 | 2008-09-25 | Progenics Pharmaceuticals, Inc. | N-Oxides of 4,5-Epoxy-Morphinanium Analogs |
| US9040726B2 (en) | 2007-03-06 | 2015-05-26 | Mallinckrodt Llc | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts |
| US20090053329A1 (en) | 2007-03-19 | 2009-02-26 | Acadia Pharmaceuticals, Inc. | Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics |
| AU2008255049A1 (en) | 2007-05-16 | 2008-11-27 | Rensselaer Polytechnic Institute | Fused-ring heterocycle opioids |
| CA2694497C (en) | 2007-08-09 | 2016-07-12 | Rensselaer Polytechnic Institute | Quaternary opioid carboxamides |
| AU2009214500B2 (en) * | 2008-02-14 | 2014-10-23 | Alkermes, Inc. | Selective opioid compounds |
| US8138169B2 (en) | 2008-04-11 | 2012-03-20 | Comgenrx, Inc. | Combination therapy for bipolar disorder |
| JP5727374B2 (ja) | 2008-07-21 | 2015-06-03 | レンセラール ポリテクニック インスティチュート | 大型置換基を有する非フェノール性アミンオピオイド |
| JP5555890B2 (ja) * | 2009-03-19 | 2014-07-23 | アルカーメス ファーマ アイルランド リミテッド | 高い経口バイオアベイラビリティを有するモルフィナン誘導体 |
| US20120149724A1 (en) | 2009-06-04 | 2012-06-14 | The General Hospital Corporation | Modulating endogenous beta-endorphin levels |
| TR201908514T4 (tr) | 2009-12-04 | 2019-07-22 | Alkermes Pharma Ireland Ltd | İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇ |
| ES2582306T3 (es) | 2010-03-22 | 2016-09-12 | Rensselaer Polytechnic Institute | Derivados de morfinano que contienen un grupo carboxamida como ligandos de receptores opioides |
| EP2590649B1 (en) | 2010-07-08 | 2018-11-28 | Alkermes Pharma Ireland Limited | Process for the synthesis of substituted morphinans |
| WO2012018872A1 (en) | 2010-08-04 | 2012-02-09 | Mallinckrodt Llc | N-demethylation of 6-keto morphinans |
| HRP20240109T1 (hr) | 2010-08-23 | 2024-03-29 | Alkermes Pharma Ireland Limited | Postupci za liječenje povećanja tjelesne težine induciranog antipsihoticima |
| WO2012088494A1 (en) | 2010-12-23 | 2012-06-28 | Pheonix Pharmalabs, Inc. | Novel morphinans useful as analgesics |
| US9211293B2 (en) | 2011-12-15 | 2015-12-15 | Alkermes Pharma Ireland Limited | Opioid agonist antagonist combinations |
| HUE041883T2 (hu) | 2011-12-15 | 2019-06-28 | Alkermes Pharma Ireland Ltd | Samidorphan (ALKS 33) és buprenorfin kombináció, depressziós zavarok kezelésére |
-
2010
- 2010-10-13 TR TR2019/08514T patent/TR201908514T4/tr unknown
- 2010-10-13 JP JP2012542008A patent/JP5691042B2/ja active Active
- 2010-10-13 RS RS20190761A patent/RS58894B1/sr unknown
- 2010-10-13 EP EP10834900.2A patent/EP2506712B8/en active Active
- 2010-10-13 ES ES10834900T patent/ES2729679T3/es active Active
- 2010-10-13 PT PT10834900T patent/PT2506712T/pt unknown
- 2010-10-13 US US12/903,462 patent/US9119848B2/en active Active
- 2010-10-13 PL PL10834900T patent/PL2506712T3/pl unknown
- 2010-10-13 DK DK10834900.2T patent/DK2506712T3/da active
- 2010-10-13 SI SI201031896T patent/SI2506712T1/sl unknown
- 2010-10-13 SM SM20190357T patent/SMT201900357T1/it unknown
- 2010-10-13 NZ NZ60037910A patent/NZ600379A/en unknown
- 2010-10-13 CA CA2782529A patent/CA2782529C/en active Active
- 2010-10-13 HU HUE10834900A patent/HUE043963T2/hu unknown
- 2010-10-13 WO PCT/US2010/052437 patent/WO2011068594A1/en active Application Filing
- 2010-10-13 ME MEP-2019-167A patent/ME03468B/me unknown
- 2010-10-13 AU AU2010326676A patent/AU2010326676B2/en active Active
- 2010-10-13 EP EP19164844.3A patent/EP3569234A1/en not_active Withdrawn
- 2010-10-13 LT LTEP10834900.2T patent/LT2506712T/lt unknown
-
2014
- 2014-10-23 JP JP2014216538A patent/JP6216305B2/ja active Active
-
2015
- 2015-08-25 US US14/835,176 patent/US20160051535A1/en not_active Abandoned
-
2017
- 2017-06-05 US US15/613,431 patent/US20170333422A1/en not_active Abandoned
-
2019
- 2019-05-21 CY CY20191100540T patent/CY1121646T1/el unknown
- 2019-06-07 HR HRP20191029TT patent/HRP20191029T1/hr unknown
-
2020
- 2020-02-07 US US16/784,574 patent/US20200345718A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010326676A1 (en) | 2012-06-21 |
| NZ600379A (en) | 2014-05-30 |
| AU2010326676B2 (en) | 2013-03-14 |
| US20200345718A1 (en) | 2020-11-05 |
| JP6216305B2 (ja) | 2017-10-18 |
| SMT201900357T1 (it) | 2019-07-11 |
| PL2506712T3 (pl) | 2019-09-30 |
| AU2010326676A2 (en) | 2012-08-30 |
| EP2506712A1 (en) | 2012-10-10 |
| HUE043963T2 (hu) | 2019-09-30 |
| ES2729679T3 (es) | 2019-11-05 |
| US20110136848A1 (en) | 2011-06-09 |
| ME03468B (me) | 2020-01-20 |
| EP2506712A4 (en) | 2013-07-10 |
| US20170333422A1 (en) | 2017-11-23 |
| DK2506712T3 (da) | 2019-06-03 |
| EP2506712B1 (en) | 2019-03-27 |
| JP2013512901A (ja) | 2013-04-18 |
| LT2506712T (lt) | 2019-06-25 |
| CA2782529C (en) | 2015-05-26 |
| RS58894B1 (sr) | 2019-08-30 |
| JP2015038139A (ja) | 2015-02-26 |
| WO2011068594A1 (en) | 2011-06-09 |
| EP2506712B8 (en) | 2019-06-19 |
| TR201908514T4 (tr) | 2019-07-22 |
| CA2782529A1 (en) | 2011-06-09 |
| US20160051535A1 (en) | 2016-02-25 |
| US9119848B2 (en) | 2015-09-01 |
| JP5691042B2 (ja) | 2015-04-01 |
| CY1121646T1 (el) | 2020-07-31 |
| PT2506712T (pt) | 2019-05-31 |
| EP3569234A1 (en) | 2019-11-20 |
| SI2506712T1 (sl) | 2019-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191029T1 (hr) | Derivati morfinana radi liječenja predoziranja lijekom | |
| RU2016105581A (ru) | Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться | |
| RU2007132181A (ru) | ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| EA201100313A1 (ru) | Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом | |
| BRPI0712976A2 (pt) | uso de 2-aminotetralinas substituÍdas para a fabricaÇço de um medicamento para a prevenÇço, alÍvio e/ou tratamento de vÁrios tipos de dor | |
| WO2009017838A3 (en) | Combinations of jak-2 inhibitors and other agents | |
| WO2012007159A3 (en) | Novel gastro-retentive dosage forms | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| WO2006031856A3 (en) | Biosynchronous transdermal drug delivery | |
| MX344308B (es) | Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso. | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| ITBO20110012A1 (it) | Composizioni farmaceutiche comprendenti rifaximina e loro uso. | |
| HRP20140592T1 (hr) | Poboljšani medicinski pripravci koji sadrže buprenorfin i naltrekson | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| WO2007123865A3 (en) | Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists | |
| GEP20146080B (en) | Chromone derivatives, method of their preparation and therapeutic applications | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| MX2011011058A (es) | Antagonistas del receptor ep4 para el tratamiento de cancer. | |
| HRP20140591T1 (hr) | Poboljšani medicinski pripravci koji sadrže buprenorfin i nalmefen | |
| CA2648518A1 (en) | Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor | |
| AR084093A1 (es) | Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica | |
| NZ719087A (en) | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome | |
| RU2011150619A (ru) | Комбинация ингибитора фосфоинозитид-3-киназы и противодиабетического соединения | |
| EA200870182A1 (ru) | Применение комбинации морфина и по меньшей мере одного антагониста опиатов для лечения зависимости от опиатов для предотвращения непероральной опиатомании у наркоманов |